Fate Stock Based Compensation from 2010 to 2025
| FATE Stock | USD 0.85 0.03 3.41% |
Stock Based Compensation | First Reported 2012-09-30 | Previous Quarter 11.8 M | Current Value 9.1 M | Quarterly Volatility 6.2 M |
Check Fate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fate Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.9 M, Interest Expense of 7.1 M or Selling General Administrative of 77.9 M, as well as many indicators such as Price To Sales Ratio of 13.07, Dividend Yield of 0.0 or PTB Ratio of 0.56. Fate financial statements analysis is a perfect complement when working with Fate Therapeutics Valuation or Volatility modules.
Fate | Stock Based Compensation |
Latest Fate Therapeutics' Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of Fate Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Fate Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fate Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
Fate Stock Based Compensation Regression Statistics
| Arithmetic Mean | 19,291,091 | |
| Geometric Mean | 5,192,571 | |
| Coefficient Of Variation | 124.42 | |
| Mean Deviation | 19,441,363 | |
| Median | 6,293,000 | |
| Standard Deviation | 24,001,924 | |
| Sample Variance | 576.1T | |
| Range | 78.6M | |
| R-Value | 0.76 | |
| Mean Square Error | 264T | |
| R-Squared | 0.57 | |
| Significance | 0.0007 | |
| Slope | 3,813,697 | |
| Total Sum of Squares | 8641.4T |
Fate Stock Based Compensation History
Other Fundumenentals of Fate Therapeutics
Fate Therapeutics Stock Based Compensation component correlations
Click cells to compare fundamentals
About Fate Therapeutics Financial Statements
Fate Therapeutics stakeholders use historical fundamental indicators, such as Fate Therapeutics' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Fate Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fate Therapeutics' assets and liabilities are reflected in the revenues and expenses on Fate Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fate Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation | 41.5 M | 22.5 M | |
| Stock Based Compensation To Revenue | 3.04 | 3.20 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Fate Therapeutics Correlation against competitors. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.69) | Revenue Per Share | Quarterly Revenue Growth 0.11 | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.